Prognostic role of p53 in stage III non-small cell lung cancer

Anticancer Res. 2005 May-Jun;25(3c):2385-9.

Abstract

Background: New biological factors have not been extensively studied in stage III non-small cell lung cancer (NSCLC). We aimed to determine the role of p53 as a prognostic factor in such patients.

Materials and methods: p53 expression was assessed by immunohistochemistry and evaluated by three independent observers. The Cox model was used to assess the impact of clinical and biological factors on patient survival.

Results: Between 01/1987 and 07/2002, 93 stage III NSCLC patients were included. Twenty-eight had a p53-positive tumour. There was no survival difference among patients with p53-positive and -negative tumours (p = 0.46). In multivariate analysis, 3 factors were statistically significantly associated with survival: surgical resection (p = 0.009), good performance status (p = 0.02) and low creatinine level (p = 0.02).

Conclusion: Good performance status, surgical resection and low creatinine level were independent favourable prognostic factors for survival in stage III NSCLC, while p53 was not, even in univariate analysis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / biosynthesis
  • Carcinoma, Non-Small-Cell Lung / metabolism*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Proportional Hazards Models
  • Tumor Suppressor Protein p53 / biosynthesis*

Substances

  • Biomarkers, Tumor
  • Tumor Suppressor Protein p53